Impaired G protein coupling of the neurotensin receptor 1 by mutations in extracellular loop 3

European Journal of Pharmacology

Volumn 433, Issue 1, 2001, Pages 63-71

  Richard, Françoise ^a   Barroso, Séverine ^a   Nicolas Ethève, Delphine ^a   Kitabgi, Patrick ^b   Labbé Jullié, Catherine ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Tel: +33 4 93 95 77 64 ^*  (France)

Author keywords

cAMP; G protein coupled receptor; Inositol phosphate; Mutagenesis; Neurotensin receptor 1; Transduction, impaired

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL PHOSPHATE; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG RECEPTOR BINDING; FIBROBLAST; MONKEY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; COS CELLS; CYCLIC AMP; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INOSITOL PHOSPHATES; MUTATION; NEUROTENSIN; RECEPTORS, NEUROTENSIN; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035861871     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01496-0     Document Type: Article

References (27)

1. Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1
2. Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line
3. Molecular cloning of a levocabastine-sensitive neurotensin binding site
4. Role of transmembrane helix IV in G-protein specificity of the angiotensin II type 1 receptor
5. G protein-coupled receptors. II. Mechanism of agonist activation
6. Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor
7. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor
8. The C9 methyl group of retinal interacts with glycine-121 in rhodopsin
9. G protein-coupled receptors: I. Diversity of receptor-ligand interactions
10. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation
11. Does neurotensin mediate the effects of antipsychotic drugs?
12. Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways
13. Pharmacology and biochemistry of neurotensin receptors
14. 3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist domains on the rat neurotensin receptor
15. Mutagenesis and modeling of the neurotensin receptor NTS1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist
16. Constitutive activity of receptors coupled to guanine nucleotide regulatory protein
17. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain
18. Ligand: A versatile computerized approach for characterization of ligand-binding systems
19. Proposed ligand binding site of the transmembrane receptor for neurotensin (8-13)
20. Characteristics for a salt-bridge switch mutation of the α1b. adrenergic receptor. Altered pharmacology and rescue of constitutive activity
21. Constitutively active mutant of rhodopsin
22. Neurotensin and neuroendocrine regulation
23. The use of non peptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interaction
24. Neurotensin
25. Neurotensin and neurotensin receptors
26. 2A-adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists
27. Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells